Target family: Voltage-gated potassium channels (K<sub>v</sub>) (type: vgic)
Target: K<SUB>v</SUB>1.3

Ligand: 5-(4-phenoxybutoxy)psoralen (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 8.7 pEC50
Reference (Journal): Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
Published in: Mol Pharmacol

Ligand: charybdotoxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 8.6 pKd
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: charybdotoxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Charybdotoxin blocks voltage-gated K+ channels in human and murine T lymphocytes.
Published in: J Gen Physiol

Ligand: charybdotoxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Cloning, functional expression, and regulation of two K+ channels in human T lymphocytes.
Published in: J Biol Chem

Ligand: charybdotoxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences.
Published in: J Biol Chem

Ligand: correolide (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.099999904632568 pIC50
Reference (Journal): Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3.
Published in: Biochemistry

Ligand: correolide (Natural product)
Interaction type: Channel blocker
Action: Pore blocker
Ligand approved: no
Primary target: no
Median affinity: 8 pKd
Reference (Journal): Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3.
Published in: Biochemistry

Ligand: HsTX1[R14A] (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: yes
Median affinity: 10.569999694824219 pIC50
Reference (Journal): Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
Published in: Clin Immunol

Ligand: kaliotoxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 9.2 pIC50
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: margatoxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences.
Published in: J Biol Chem

Ligand: margatoxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels.
Published in: J Biol Chem

Ligand: maurotoxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.800000190734863 pIC50
Reference (Journal): Maurotoxin, a four disulfide bridges scorpion toxin acting on K+ channels.
Published in: Toxicon

Ligand: noxiustoxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 9 pKd
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: OSK1-K16-D20 (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity: 11.5 pIC50
Reference (Journal): K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom.
Published in: Biochem J

Ligand: psora-4 (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 6.139999866485596 pIC50
Reference (Journal): N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 inhibitors. Part 1.
Published in: Bioorg Med Chem Lett

Ligand: ShK(L5) (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Published in: Mol Pharmacol

Ligand: ShK Toxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Substitution of a single residue in Stichodactyla helianthus peptide, ShK-Dap22, reveals a novel pharmacological profile.
Published in: Biochemistry

Ligand: ShK Toxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone.
Published in: Int J Pept Protein Res

Ligand: ShK Toxin (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide.
Published in: J Biol Chem

Ligand: tetraethylammonium (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 2 pKd
Reference (Journal): Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
Published in: Mol Pharmacol

Ligand: Vm24 (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: yes
Median affinity: 12.300000190734863 pKd
Reference (Journal): Structure, function, and chemical synthesis of Vaejovis mexicanus peptide 24: a novel potent blocker of Kv1.3 potassium channels of human T lymphocytes.
Published in: Biochemistry

Ligand: Vm24 (Peptide)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: yes
Median affinity: 11.539999961853027 pKd
Reference (Journal): Structure, function, and chemical synthesis of Vaejovis mexicanus peptide 24: a novel potent blocker of Kv1.3 potassium channels of human T lymphocytes.
Published in: Biochemistry

Ligand: WP1066 (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 5.489999771118164 pIC50
Reference (Journal): Identification of WP1066, an inhibitor of JAK2 and STAT3, as a K<sub>V</sub> 1.3 potassium channel blocker.
Published in: Br J Pharmacol